Timolol vs propranolol vs placebo in common migraine prophylaxis: a double-blind multicenter trial
The DOI matches its Crossref record.
Abstract
Common migraine sufferers (25 males, 71 females) with a history of 2-6 attacks per month participated in a 4-centre trial comparing the prophylactic effect of timolol (10 mg b.i.d.) and propranolol (80 mg b.i.d.) to placebo. After a pretreatment period of 4 weeks they entered a double-blind 3-way cross-over trial with 3 treatment periods of 12 weeks each. 83 patients received all 3 treatments. The mean frequency of attacks per 28 days was 3.35 on timolol, 3.69 on propranolol and 4.83 on placebo. Mean severity of attacks (0-3) was 1.75 on timolol, 1.83 on propranolol, and 1.93 on placebo. Mean duration of attacks was 7.41 h on timolol, 7.38 on propranolol and 7.95 on placebo. The headache index (frequency times severity) was 5.71 on timolol, 6.66 on propranolol and 9.03 on placebo (P less than 0.05, P less than 0.01 compared to placebo). The difference between propranolol and timolol was non-significant: frequency of attacks 0.34 (95% confidence limits - 0.26; 0.89). Headache index 0.95 propranolol and 23 patients on placebo experienced side effects (P less than 0.05). It is concluded that timolol and propranolol are equally effective in the used doses (1:8) for common migraine prophylaxis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
EFNS guideline on the drug treatment of migraine—revised report of an EFNS task force
Evers, S., Áfra, J., Frese, A., Goadsby, P. J., Linde, M., May, A., & Sándor, P. S. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02748.x · Cited by 892
Guidelines for Controlled Trials of Drugs in Migraine: Second Edition
International Headache Society Clinical Trials Subcommittee, Tfelt-Hansen, P., Block, G., Dahlöf, C., Diener, H.-C., Ferrari, M., Goadsby, P., Guidetti, V, Jones, B., Lipton, R., et al. (2000) · Cephalalgia · doi:10.1046/j.1468-2982.2000.00117.x · Cited by 698
Self-citationTopiramate in Migraine Prevention: Results of a Large Controlled Trial
Silberstein, S. D. (2004) · Archives of Neurology · doi:10.1001/archneur.61.4.490 · Cited by 529
Guidelines for controlled trials of drugs in migraine: Third edition. A guide for investigators
International Headache Society Clinical Trials Subcommittee members:, Tfelt-Hansen, P., Pascual, J., Ramadan, N., Dahlöf, C., D'Amico, D., Diener, H.-C., Hansen, J. M., Lanteri-Minet, M., Loder, E., et al. (2012) · Cephalalgia · doi:10.1177/0333102411417901 · Cited by 365
Self-citationSystematic Review of Migraine Prophylaxis Adherence and Persistence
Hepp, Z., Bloudek, L. M., & Varon, S. F. (2014) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2014.20.1.22 · Cited by 333
Metadata
- Authors
- Tfelt-Hansen, P., Standnes, B., Kangasneimi, P., Hakkarainen, H., & Olesen, J.
- Venue
- Acta Neurologica Scandinavica
- Publisher
- Hindawi Limited
- Published
- 1984-01
- Volume
- 69
- Issue
- 1
- Pages
- 1-8
- ISSN
- 0001-6314 (ISSN-L)
- 1600-0404
- OpenAlex
- W1988012785
- Cited by
- 146
- References
- 0
- FWCI
- 3.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Timolol vs propranolol vs placebo in common migraine prophylaxis: a double-blind multicenter trial. https://app.cochat.ai/papers/10.1111/j.1600-0404.1984.tb07772.x
- The paper
- Tfelt-Hansen, P., Standnes, B., Kangasneimi, P., Hakkarainen, H., & Olesen, J. (1984). Timolol vs propranolol vs placebo in common migraine prophylaxis: a double-blind multicenter trial. Acta Neurologica Scandinavica. https://doi.org/10.1111/j.1600-0404.1984.tb07772.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.